An Expert Approach to Individualizing Care for Patients with Fibromyalgia

Daniel J. Clauw, MD, describes the role the brain and CNS play in controlling the setting of nociplastic pain in patients with fibromyalgia and highlights increased patient sensitivity to sensory stimuli.

Dr Daniel J. Clauw provides an overview of pharmacologic and nonpharmacologic therapeutic approaches for the management of fibromyalgia and comments on challenges and unmet needs for patients.

Daniel J. Clauw, MD, shares his approach to selecting FDA approved therapeutic agents for fibromyalgia treatment and his clinical treatment strategy when first-line pharmacological therapy fails.

Dr Daniel J. Clauw shares clinical pearls for the treatment of patients with fibromyalgia and comments on future developments in the pipeline for disease management.

Philip J. Mease, MD, provides an overview of fibromyalgia as a primary disorder of central pain processing and modulation.

Philip J. Mease, MD, comments on the importance of education about fibromyalgia, especially regarding the stigma and the psychological impact of the disease.

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.